Januari 2012
29
6.1
Reference
List
1.
Lindblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary tyrosinemia.
Proc Natl
Acad Sci U S A.
1977;74:4641-4645.
2.
Sniderman KL, Trahms C, Scott CR. Tyrosinemia Type 1. 1993.
3.
Russo PA, Mitchell GA, Tanguay RM. Tyrosinemia: a review.
Pediatr Dev Pathol.
2001;4:212-
221.
4.
van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V, et al. Hereditary
tyrosinemia type I: a new clinical classification with difference in prognosis on dietary
treatment.
Hepatology.
1994;20:1187-1191.
5.
Koelink CJ, van HP, van der Ploeg A, van den Heuvel-Eibrink MM, Wijburg FA, Bijleveld CM, et
al. Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer?
Mol Genet Metab.
2006;89:310-315.
6.
Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, et al. NTBC
treatment in tyrosinaemia type I: long-term outcome in French patients.
J Inherit Metab Dis.
2008;31:81-87.
7.
McKiernan PJ. Nitisinone in the treatment of hereditary tyrosinaemia type 1.
Drugs.
2006;66:743-750.
8.
Holme E, Lindstedt S. Nontransplant treatment of tyrosinemia.
Clin Liver Dis.
2000;4:805-814.
9.
Ashorn M, Pitkanen S, Salo MK, Heikinheimo M. Current strategies for the treatment of
hereditary tyrosinemia type I.
Paediatr Drugs.
2006;8:47-54.
10.
Tanguay RM, Lambert M, Grompe M, Mitchell GA. Hypertyrosinemia. In: Valle D, Beaudet A,
Vogelstein B, Kinzler K, Antonarakis S, Ballabio A, editors. Scriver's Metabolic and Molecular
Bases of Inherited Diseases Online. The Online Metabolic and Molecular Bases of Inherited
Diseases ed.
New York
:
McGraw-Hill
; 2011.
11.
Mohan N, McKiernan P, Preece MA, Green A, Buckels J, Mayer AD, et al. Indications and
outcome of liver transplantation in tyrosinaemia type 1.
Eur J Pediatr.
1999;158
Suppl 2:S49-
S54.
12.
Pierik LJ, van Spronsen FJ, Bijleveld CM, van Dael CM. Renal function in tyrosinaemia type I
after liver transplantation: a long-term follow-up.
J Inherit Metab Dis.
2005;28:871-876.
13.
van Spronsen FJ, Bijleveld CM, van Maldegem BT, Wijburg FA. Hepatocellular carcinoma in
hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-
cyclohexanedione treatment.
J Pediatr Gastroenterol Nutr.
2005;40:90-93.
14.
Ahmad S, Teckman JH, Lueder GT. Corneal opacities associated with NTBC treatment.
Am J
Ophthalmol.
2002;134:266-268.
15.
Gissen P, Preece MA, Willshaw HA, McKiernan PJ. Ophthalmic follow-up of patients with
tyrosinaemia type I on NTBC.
J Inherit Metab Dis.
2003;26:13-16.
16.
Arora N, Stumper O, Wright J, Kelly DA, McKiernan PJ. Cardiomyopathy in tyrosinaemia type I
is common but usually benign.
J Inherit Metab Dis.
2006;29:54-57.